KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Deferred Revenue (2017 - 2025)

Aquestive Therapeutics has reported Current Deferred Revenue over the past 9 years, most recently at $20.5 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $20.5 million for Q4 2025, up 1854.39% from a year ago — trailing twelve months through Dec 2025 was $20.5 million (up 1854.39% YoY), and the annual figure for FY2025 was $20.5 million, up 1854.39%.
  • Current Deferred Revenue for Q4 2025 was $20.5 million at Aquestive Therapeutics, up from $1.1 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for AQST hit a ceiling of $37.1 million in Q2 2023 and a floor of $642000.0 in Q2 2021.
  • Median Current Deferred Revenue over the past 5 years was $6.6 million (2021), compared with a mean of $13.2 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 2220.95% in 2023 and later plummeted 97.04% in 2024.
  • Aquestive Therapeutics' Current Deferred Revenue stood at $765000.0 in 2021, then surged by 97.78% to $1.5 million in 2022, then skyrocketed by 2140.32% to $33.9 million in 2023, then crashed by 96.91% to $1.0 million in 2024, then skyrocketed by 1854.39% to $20.5 million in 2025.
  • The last three reported values for Current Deferred Revenue were $20.5 million (Q4 2025), $1.1 million (Q3 2025), and $21.0 million (Q2 2025) per Business Quant data.